2020
Use of Gadolinium-Based Contrast Agents in Kidney Disease Patients: Time for Change
Abu-Alfa AK. Use of Gadolinium-Based Contrast Agents in Kidney Disease Patients: Time for Change. American Journal Of Kidney Diseases 2020, 76: 436-439. PMID: 32283121, DOI: 10.1053/j.ajkd.2020.03.011.Commentaries, Editorials and Letters
2014
Advancing pharmacovigilance through academic–legal collaboration: the case of gadolinium-based contrast agents and nephrogenic systemic fibrosis—a research on adverse drug events and reports (RADAR) report
Edwards BJ, Laumann AE, Nardone B, Miller FH, Restaino J, Raisch DW, McKoy JM, Hammel JA, Bhatt K, Bauer K, Samaras AT, Fisher MJ, Bull C, Saddleton E, Belknap SM, Thomsen HS, Kanal E, Cowper SE, Abu Alfa AK, West DP. Advancing pharmacovigilance through academic–legal collaboration: the case of gadolinium-based contrast agents and nephrogenic systemic fibrosis—a research on adverse drug events and reports (RADAR) report. British Journal Of Radiology 2014, 87: 20140307. PMID: 25230161, PMCID: PMC4170864, DOI: 10.1259/bjr.20140307.Peer-Reviewed Original ResearchConceptsGadolinium-based contrast agentsAdverse drug eventsDrug eventsMedicines AgencyGadopentetate dimeglumineDrug Administration Adverse Event Reporting SystemAdverse Event Reporting SystemDanish Medicines AgencyNephrogenic systemic fibrosisEvent Reporting SystemEuropean Medicines AgencyNSF casesHistopathological dataContrast agentsSystemic fibrosisDrug AdministrationLegal data setsUnconfounded casesGadobenate dimeglumineMean numberDimeglumineReporting systemPharmacovigilance researchSafety informationPharmacovigilance
2011
Nephrogenic Systemic Fibrosis and Gadolinium-Based Contrast Agents
Abu-Alfa AK. Nephrogenic Systemic Fibrosis and Gadolinium-Based Contrast Agents. Advances In Kidney Disease And Health 2011, 18: 188-198. PMID: 21531325, DOI: 10.1053/j.ackd.2011.03.001.Peer-Reviewed Original ResearchMeSH KeywordsContrast MediaGadoliniumHumansKidney DiseasesMagnetic Resonance ImagingNephrogenic Fibrosing DermopathyRisk FactorsConceptsAcute kidney injuryNephrogenic systemic fibrosisGadolinium-based contrast agentsCKD stage 4Immediate hemodialysisSystemic fibrosisAdministration of GBCAsCare of patientsStage 4Needs of patientsMajority of casesKidney injuryDialysis initiationPeritoneal dialysisSignificant morbidityKidney diseaseCurrent recommendationsHigh riskContrast agentsLower riskRisk differencePatientsDrug AdministrationHemodialysisIndividualized assessment
2009
Gadolinium‐based contrast agents and nephrogenic systemic fibrosis: Why did it happen and what have we learned?
Weinreb JC, Abu‐Alfa A. Gadolinium‐based contrast agents and nephrogenic systemic fibrosis: Why did it happen and what have we learned? Journal Of Magnetic Resonance Imaging 2009, 30: 1236-1239. PMID: 19938035, DOI: 10.1002/jmri.21979.Commentaries, Editorials and LettersMeSH KeywordsContrast MediaGadoliniumHumansMagnetic Resonance ImagingNephrogenic Fibrosing Dermopathy
2008
Nephrogenic systemic fibrosis—Implications for nephrologists
Saab G, Abu-Alfa A. Nephrogenic systemic fibrosis—Implications for nephrologists. European Journal Of Radiology 2008, 66: 208-212. PMID: 18342470, DOI: 10.1016/j.ejrad.2008.01.028.BooksMeSH KeywordsContrast MediaFibrosisGadoliniumHumansKidney DiseasesMagnetic Resonance ImagingRisk FactorsSkin DiseasesConceptsRisk of NSFChronic kidney diseaseNephrogenic systemic fibrosisContrast-induced nephropathyAdvanced chronic kidney diseaseDevelopment of NSFAdministration of gadoliniumErythropoietin therapyNephrologist's perspectiveKidney diseaseMetabolic acidosisRisk factorsMineral metabolismSystemic fibrosisNephrologist's roleHigh dosesGd-CARecent evidenceRiskContrast agentsNephropathyNephrologistsPatientsFibrosisAcidosisThe Impact of NSF on the Care of Patients With Kidney Disease
Abu-Alfa A. The Impact of NSF on the Care of Patients With Kidney Disease. Journal Of The American College Of Radiology 2008, 5: 45-52. PMID: 18180009, DOI: 10.1016/j.jacr.2007.08.018.Peer-Reviewed Original ResearchMeSH KeywordsAcidosisContrast MediaFibrosisGadoliniumHumansKidney DiseasesMagnetic Resonance ImagingRisk FactorsSkinSkin DiseasesConceptsEnd-stage renal diseaseChronic kidney diseaseNephrogenic systemic fibrosisGlomerular filtration rateCare of patientsGadolinium-based magnetic resonance contrast agentsRenal diseasePeritoneal dialysisKidney diseaseFiltration rateSystemic fibrosisStage 4 chronic kidney diseaseCases of NSFNormal glomerular filtration rateAcute kidney injurySessions of hemodialysisMajority of casesCKD patientsKidney injuryMagnetic resonance contrast agentsSignificant morbidityPD patientsVascular accessProlonged eliminationOdds ratio
2007
Are Patients with Moderate Renal Failure at Risk for Developing Nephrogenic Systemic Fibrosis?
Saab G, Abu-Alfa A. Are Patients with Moderate Renal Failure at Risk for Developing Nephrogenic Systemic Fibrosis? Radiology 2007, 244: 930-932. PMID: 17709844, DOI: 10.1148/radiol.2443070351.Peer-Reviewed Original ResearchGadolinium-based MR Contrast Agents and Nephrogenic Systemic Fibrosis1
Kuo PH, Kanal E, Abu-Alfa AK, Cowper SE. Gadolinium-based MR Contrast Agents and Nephrogenic Systemic Fibrosis1. Radiology 2007, 242: 647-9. PMID: 17213364, DOI: 10.1148/radiol.2423061640.Commentaries, Editorials and Letters